Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Former NIH Director Bernadine P. Healy dies

You may also be interested in...



People In Brief

FDA 510(k) director joins Greenleaf: Heather Rosecrans Sept. 28 follows former CDRH Director Dan Schultz to the consulting firm Greenleaf Health, where she will serve as a senior regulatory advisor working with Greenleaf clients to advance innovative devices (1"The Gray Sheet" Sept. 20, 2010). Other former FDAers at Greenleaf include former deputy chief of staff Taryn Fritz Warpole and former FDA Commissioner Andrew von Eschenbach. Former FDA Chief of Staff Patrick Ronan founded the Washington, D.C., and Portola Valley, Calif., firm

Genetic Testing Policy Options: Federal Agency, Expanded Oversight – Report

Federal approaches to regulating pre-implantation genetic diagnosis (PGD) could entail creating a dedicated agency or giving an existing agency oversight of the procedure, a new report from the Genetics & Public Policy Center at Johns Hopkins University says

Keep Makena Under Accelerated Approval Pending More Studies, AMAG Tells US FDA

AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.

Topics

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel